Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib + Trastuzumab + XELOX in 1L HER2+ Advanced Gastric/GEJ Adenocarcinoma
NCT07334431Phase 2Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Feb 2024
- Primary completion
- Dec 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of fruquintinib in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Henan Cancer Hospital. Started Feb 2024; status: recruiting.
02
Drugs
fruquintinib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07334431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07334431.